利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.024 秒)

    Chimeric chlorotoxin receptors
    3.
    发明授权
    Chimeric chlorotoxin receptors 有权

    公开(公告)号：US11421005B2

    公开(公告)日：2022-08-23

    申请号：US16467467

    申请日：2017-12-09

    申请人： The UAB Research Foundation

    发明人： Lawrence S. Lamb, Jr. ,  Antonio Di Stasi ,  G. Yancey Gillespie ,  Larisa Pereboeva

    IPC分类号： A61K35/17 ,  C07K14/435 ,  A61K38/17 ,  A61K45/06 ,  C07K14/725 ,  C07K14/705

    摘要： The invention provides chimeric antigen receptor(s) (CAR(s)) that comprise a fusion protein of CTX or any functional variant thereof or a CTX-like peptide or any functional variant thereof as the extracellular antigen recognition moiety of the CAR. CAR(s) comprising CTX, a CTX-like peptide or functional variants of the foregoing are collectively referred to herein as “CTX-CAR(s).” Such CTX-CAR(s) may further comprise additional moieties or domains in the extracellular domain, a transmembrane domain and at least one intracellular! signaling domain. Such CTX-CAR(s) may be expressed in a host cell, such as, but not limited to, an immune effector cell. The present invention also provides methods of treatment (such as, for example, methods for treating cancer) by providing to the patient in need thereof immune effector cells that are engineered to express a CTX-CAR described herein.

    CHIMERIC CHLOROTOXIN RECEPTORS
    4.
    发明申请
    CHIMERIC CHLOROTOXIN RECEPTORS 有权

    公开(公告)号：US20230037076A1

    公开(公告)日：2023-02-02

    申请号：US17864935

    申请日：2022-07-14

    申请人： The UAB Research Foundation

    发明人： Lawrence S. Lamb, JR. ,  Antonio Di Stasi ,  G. Yancey Gillespie ,  Larisa Pereboeva

    IPC分类号： C07K14/435 ,  A61K35/17 ,  A61K38/17 ,  A61K45/06 ,  C07K14/725 ,  C07K14/705

    摘要： The invention provides chimeric antigen receptor(s) (CAR(s)) that comprise a fusion protein of CTX or any functional variant thereof or a CTX-like peptide or any functional variant thereof as the extracellular antigen recognition moiety of the CAR. CAR(s) comprising CTX, a CTX-like peptide or functional variants of the foregoing are collectively referred to herein as “CTX-CAR(s).” Such CTX-CAR(s) may further comprise additional moieties or domains in the extracellular domain, a transmembrane domain and at least one intracellular signaling domain. Such CTX-CAR(s) may be expressed in a host cell, such as, but not limited to, an immune effector cell. The present invention also provides methods of treatment (such as, for example, methods for treating cancer) by providing to the patient in need thereof immune effector cells that arc engineered to express a CTX-CAR described herein.